EUVIMEDEUVIMED entdecken
Crossref

Structural and Physicochemical Features of Oral PROTACs

Markus Schade iD, James S Scott iD, Thomas G Hayhow iD, Andy Pike iD, Ina Terstiege iD, Marie Ahlqvist iD, Johan R Johansson iD, Coura R Diene iD, Charlene Fallan iD, Amber Y S Balazs iD, Elisabetta Chiarparin iD, David Wilson

Journal of Medicinal Chemistry · 08.08.2024 · 67 (15) · 13106-13116

DOI: 10.1021/acs.jmedchem.4c01017 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 30.07.2024. Verfasst von Markus Schade und 11 weiteren Autor:innen. Beteiligte Einrichtung: Chemistry and DMPK, Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, United Kingdom. Hauptthemen laut MEDLINE: Biological Availability, Proteolysis. Die Arbeit wurde bisher 81-mal zitiert (Crossref) und nennt 59 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Achieving oral bioavailability with Proteolysis Targeting Chimeras (PROTACs) is a key challenge. Here, we report the in vivo pharmacokinetic properties in mouse, rat, and dog of four clinical oral PROTACs and compare with an internally derived data set. We use NMR to determine 3D molecular conformations and structural preorganization free in solution, and we introduce the new experimental descriptors, solvent-exposed H-bond donors (eHBD), and acceptors (eHBA). We derive an upper limit of eHBD ≤ 2 for oral PROTACs in apolar environments and show a greater tolerance for other properties (eHBA, polarity, lipophilicity, and molecular weight) than for Rule-of-5 compliant oral drugs. Within a set of structurally related PROTACs, we show that examples with eHBD > 2 have much lower oral bioavailability than those that have eHBD ≤ 2. We summarize our findings as an experimental "Rule-of-oral-PROTACs" in order to assist medicinal chemists to achieve oral bioavailability in this challenging space.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biological AvailabilityProteolysisAnimalsAdministration, OralDogsMiceRatsHumansMaleHydrogen BondingProteolysis Targeting Chimera

Substanzen

Proteolysis Targeting Chimera

Autor:innen und Institutionen

  • Chemistry and DMPK, Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, United Kingdom.
  • Chemistry and DMPK, Research and Early Development, Respiratory and Immunology, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, Mölndal 43183, Sweden.
  • Chemistry, Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States.

ORCID-Profile: Markus Schade, James S Scott, Thomas G Hayhow, Andy Pike, Ina Terstiege, Marie Ahlqvist, Johan R Johansson, Coura R Diene, Charlene Fallan, Amber Y S Balazs, Elisabetta Chiarparin

Zitieren

APA

Schade, M., Scott, J. S., Hayhow, T. G., Pike, A., Terstiege, I., Ahlqvist, M., Johansson, J. R., Diene, C. R., Fallan, C., Balazs, A. Y. S., Chiarparin, E., & Wilson, D. (2024). Structural and Physicochemical Features of Oral PROTACs. Journal of Medicinal Chemistry, 67(15), 13106-13116. https://doi.org/10.1021/acs.jmedchem.4c01017

Vancouver

Schade M, Scott JS, Hayhow TG, Pike A, Terstiege I, Ahlqvist M, et al. Structural and Physicochemical Features of Oral PROTACs. Journal of Medicinal Chemistry. 2024;67(15):13106-13116. doi:10.1021/acs.jmedchem.4c01017

BibTeX
@article{Schade2024,
  author = {Schade, Markus and Scott, James S and Hayhow, Thomas G and Pike, Andy and Terstiege, Ina and Ahlqvist, Marie and Johansson, Johan R and Diene, Coura R and Fallan, Charlene and Balazs, Amber Y S and Chiarparin, Elisabetta and Wilson, David},
  title = {Structural and Physicochemical Features of Oral PROTACs},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  volume = {67},
  number = {15},
  pages = {13106--13116},
  doi = {10.1021/acs.jmedchem.4c01017}
}
Kostenlos starten →